Aronex Pharmaceuticals Inc initiated with an Outperform at Oppenheimer. Oppenheimer analyst Kevin DeGeeter started coverage of Aronex Pharmaceuticals Inc with an Outperform rating and $20 price target. The analyst cited the expectation for positive Oraxol Phase III breast cancer data in Q3, proprietary survey results suggesting potential for meaningful uptake of KX2-391 for treatment of actinic keratosis, and strength of the company’s commercial channel for specialty oncology products and opportunity for operating leverage. DeGeeter views Aronex Pharmaceuticals Inc’s Orascovery oral chemotherapy platform as offering potential for important efficacy and tolerability benefits compared to traditional IV chemotherapy, and views partnering as providing important catalysts over the next 12-24 months.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.